CoChat

Brivaracetam Disposition in Renal Impairment

Sargentini‐Maier, Maria Laura, Sokalski, Antoni, Boulanger, Pierre, Jacobs, Tom, Stockis, Armel · 2012 · The Journal of Clinical Pharmacology
Cited by 62

The DOI matches its Crossref record.

Abstract

Brivaracetam is a novel high‐affinity SV2A ligand currently in clinical development for epilepsy. The objective was to characterize its disposition in patients with renal impairment. A single oral dose of 200 mg brivaracetam was administered to 9 patients with severe renal impairment not requiring dialysis (creatinine clearance <15 mL/ min, n = 6; 15–29 mL/min, n = 3) and 9 matched healthy controls. Plasma and urinary concentrations of brivaracetam and 3 pharmacologically inactive metabolites (acid, hydroxy, and hydroxyacid) were determined up to 72 hours postdose, and noncompartmental pharmacokinetic parameters were derived. The C max of brivaracetam was unchanged relative to healthy controls, whereas AUC was slightly increased (mean ratio, 1.21; 90% confidence interval, 1.01–1.45). Nonrenal and renal clearances of brivaracetam decreased from 47 and 4.5 to 41 and 1.7 mL/min/1.73 m 2. Exposure to the acid, hydroxy, and hydroxyacid metabolites was markedly increased: C max by 2.4‐, 2.0‐, and 11.7‐fold and AUC by 3.2‐, 4.1‐, and 21.5‐fold. Renal clearance of these rapidly cleared metabolites was decreased 10‐fold in patients with severe renal impairment. Nonclinical toxicology studies concluded to the absence of safety issues related to the increased levels of metabolites. These observations suggest that dose adjustment of brivaracetam should not be required at any stage of renal dysfunction.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1177/0091270011431457

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 62

Metadata

Authors
Sargentini‐Maier, M. L., Sokalski, A., Boulanger, P., Jacobs, T., & Stockis, A.
Venue
The Journal of Clinical Pharmacology
Publisher
Wiley
Published
2012-12
Volume
52
Issue
12
Pages
1927-1933
ISSN
  • 0021-9754 (ISSN-L)
  • 0091-2700
  • 1552-4604
OpenAlex
W2065885918
Cited by
62
References
0
FWCI
3.28
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Brivaracetam Disposition in Renal Impairment. https://app.cochat.ai/papers/10.1177/0091270011431457
The paper
Sargentini‐Maier, M. L., Sokalski, A., Boulanger, P., Jacobs, T., & Stockis, A. (2012). Brivaracetam Disposition in Renal Impairment. The Journal of Clinical Pharmacology. https://doi.org/10.1177/0091270011431457

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.